94226-19-4

Usage

Uses

Used in Pharmaceutical Research:
Thieno[3,2-c]pyridine-2-carboxaldehyde (9CI) is utilized as a key intermediate in the synthesis of various pharmaceutical compounds. Its unique structure allows for the development of new drugs with potential therapeutic applications.
Used in Agrochemical Development:
Thieno[3,2-c]pyridine-2-carboxaldehyde (9CI) also serves as a building block in the creation of agrochemicals, contributing to the development of new pesticides and other agricultural chemicals to improve crop protection and yield.
Used in Organic Synthesis:
Thieno[3,2-c]pyridine-2-carboxaldehyde (9CI) is employed as a versatile reactant in organic synthesis, enabling the formation of a wide range of heterocyclic compounds with diverse applications in various industries.

Upstream product

• 272-14-0 thieno[3,2-c]pyridine 
• 109-94-4 formic acid ethyl ester 
• 68-12-2 N,N-dimethyl-formamide 
• 58754-98-6 N-(2,2-dimethoxyethyl)-4-methyl-N-(thiophen-2-ylmethyl)benzenesulfonamide 
• 58754-99-7 dimethoxy-N-(thiophen-2-ylmethyl)ethanamine 
• 98-03-3 thiophene-2-carbaldehyde 

Downstream Products

• 709649-71-8 N-methyl-1-(thieno[3,2-c]pyridin-2-yl)methanamine 
• 870774-03-1 4-{1-[5-(4-chloro-phenyl)-oxazol-2-yl]-1-methyl-ethyl}-1-[5-(2,2-dimethyl-3a,9b-dihydro-4H-chromeno[4,3-d]oxazol-1-yl)-2-hydroxy-5-oxo-4-thieno[3,2-c]pyridin-2-ylmethyl-pentyl]-piperazine-2-carboxylic acid (2,2,2-trifluoro-ethyl)-amide 

Relevant academic research and scientific papers

Design, synthesis, and antifibrosis evaluation of 4-(benzo-[c][1,2,5]thiadiazol-5-yl)-3(5)-(6-methyl- pyridin-2-yl)pyrazole and 3(5)-(6-methylpyridin- 2-yl)-4-(thieno-[3,2,-c]pyridin-2-yl)pyrazole derivatives

Six series of 4-(benzo[c][1,2,5]thiadiazol-5-yl)-3(5)-(6-methylpyridin-2-yl)- pyrazoles 18a–d, 19a–d, 22a–d and 3(5)-(6-methylpyridin-2-yl)-4-(thieno[3,2,-c]- pyridin-2-yl)pyrazoles 20a–d, 21a–d, 23c, 23d have been synthesized and evaluated for their activin receptor-like kinase 5 (ALK5) and p38α mitogen activated protein (MAP) kinase inhibitory activities in enzymatic assays. Among these compounds, the most active compound, 22c, inhibited ALK5 phosphorylation with an IC50 value of 0.030 μM in the enzymatic assay. Compound 22c showed four-fold more potent activity against ALK5 kinase than the clinical candidate, compound LY-2157299. The selectivity index of 22c against p38α MAP kinase is 235, which is much higher than that of LY-2157299 (4) and equally selective to that of EW-7197 (218). Compound 22c effectively suppressed protein and mRNA expression of collagen I and α-SMA in TGF-β-induced LX-2 human hepatic stellate cell (HSC), this result shows that compound 22c has the ability to inhibit the activation of HSC. Compound 22c is expected to be a preclinical candidate for the treatment of hepatic fibrosis.

Rational design of novel CYP2A6 inhibitors

Inhibition of CYP2A6-mediated nicotine metabolism can reduce cigarette smoking. We sought potent and selective CYP2A6 inhibitors to be used as leads for drugs useful in smoking reduction therapy, by evaluating CYP2A6 inhibitory effect of novel formyl, alk

Orally bioavailable highly potent HIV protease inhibitors against PI-resistant virus

Efforts directed to identifying potent HIV protease inhibitors (PI) have yielded a class of compounds that are not only very active against wild-type (NL4-3) HIV virus but also very potent against a panel of PI-resistant viral isolates. Chemistry and biol

HETEROCYCLIC COMPOUNDS, METHODS OF MAKING THEM AND THEIR USE IN THERAPY

In part, the present invention is directed to antibacterial compounds of formula (I) wherein A is a bicyclic heteroaryl ring or a tricyclic ring and R2 is an heterocyclic residue; L is a bond, or L is alkyl, alkenyl or cycloalkyl.

Preparation of alkali metal thieno(furo)pyridines

Thienopyridines and furopyridines react at the 2-position with non-nucleophilic alkali metal bases to give alkali metal thieno(furo)pyridine salts.